Methamphetamine Thomas E. Freese, Ph.D. Director, Pacific Southwest Addiction Technology Transfer Center Director of Training, UCLA Integrated Substance.

Slides:



Advertisements
Similar presentations
Substance Use Disorder Treatment Supporting the Field with Evidence and Logic.
Advertisements

Suicide Prevention for Older Adults: Depression is NOT Normal Aging Alan Holmlund Director MDPH Suicide Prevention Program 18 APR 07.
Models of Evaluation of Addiction Treatment Outcome Post-Treatment vs. During Treatment Evaluation of Effectiveness.
The Impact of Trauma Teaching Resilience Through Positive Adult Relationships.
CDC-NIMH Conference Closing Meditations Thomas J. Coates PhD Professor of Medicine Director, AIDS Research Institute University of California San Francisco.
 William Frank Barker, LPC, MAC Diane Diver, LMSW, CAC II.
Nora D. Volkow, M.D. Director National Institute on Drug Abuse Nora D. Volkow, M.D. Director National Institute on Drug Abuse What Do We Know? Drug Abuse.
Prevention Research (Children & Adolescents) genetics environment development co-morbidity Prevention Research (Children & Adolescents) genetics environment.
Nora D. Volkow, M.D. Director National Institute on Drug Abuse Nora D. Volkow, M.D. Director National Institute on Drug Abuse RESEARCH and TREATMENT Provide.
The Impact of Telepsychiatry for Patients with Co-morbid Disorders at a Rural County-Run Residential Treatment Clinic Presented at: Addiction Health Services.
University of Utah Department of Human Genetics The New Science of Addiction Louisa A. Stark, Ph.D. Director.
HIV/AIDS and Substance Use Disorders Olivera J. Bogunovic, M.D. State University of New York at Buffalo Alcohol Medical Scholars Program.
Bringing the Full Power of Science to Bear on Bringing the Full Power of Science to Bear on NIDA NATIONAL INSTITUTE ON DRUG ABUSE Drug Abuse & Addiction.
Understanding Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
PREVENTING HIV AND OTHER STDs
Treatment of Methamphetamine Dependence: Does Treatment Work? Mary Lynn Brecht, Ph.D. Richard A. Rawson, Ph.D Semel Institute for Neuroscience and Human.
Treatment of Methamphetamine Dependence: A brief overview Richard A. Rawson, Ph.D Adjunct Associate Professor Semel Institute for Neuroscience and Human.
Addressing Crystal Methamphetamine Use Among Gay and Bisexual Men: A Treatment Center’s Response Joe Ruggiero, Ph.D. –Director, Outpatient Services The.
Rural Crime & Justice Center A University Center of Excellence Minot, North Dakota.
Methamphetamine: How it Influences the Brain and Behavior of Users
Substance Abuse: Testing HIV, Meth and Other Issues Thomas E. Freese, Ph.D. Director, Pacific Southwest Addiction Technology Transfer Center Director of.
Dr Pamela Smith – Fall  Definition = development of resources necessary to provide mental health care within a given setting or community  Function.
Methamphetamine use in South Africa: Do increased rates of methamphetamine smoking represent an HIV transmission threat? Richard A. Rawson, Ph.D Adjunct.
Meeting the health needs of older drug users Dr Muriel Simmonte NHS Lothian Primary Care Facilitator Team/East Lothian Locality Drug Clinic.
Recovery Oriented Systems of Care in Minnesota
Mental Health and Substance Abuse Services Joe Vesowate Assistant Commissioner.
Sarah E. Cavanaugh Addiction Therapy-2014 Chicago, USA August 4 - 6, 2014.
LOVE IN THE TIME OF CRYSTAL METHAMPHETAMINE World Psychiatric Association Athens, Greece March 15, 2005 Petros Levounis, M.D. Director, The Addiction.
Greenberg&Cohen EBCRP Methamphetamine: Understanding the Influence of Violence in Treatment Planning and Recovery Judith Cohen, PhD Rivka Greenberg, PhD.
Responding to Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
Richard Rawson, Ph.D. Valerie Pearce, M.P.H. Rachel Gonzales, Ph.D. Julie Brummer, B.A. UCLA Integrated Substance Abuse Programs May 8, 2007 Treatment.
Cultural Competency, HIV, & Stimulants HIV, Mental Health, the Brain, & Stimulants January 31, 2006 I. Jean Davis, PhD, DC, PA Assistant Professor, Dept.
ABSTRACT Introduction: HIV infection is growing relatively fast among seniors. Among the clinical implications are that older patients have less ability.
The National Prevention Strategy and Behavioral Health Care: Prevention Is Now RADM Peter J. Delany, Ph.D., LCSW-C Substance Abuse and Mental Health Services.
Methamphetamine and the Brain: New Knowledge; New Treatments Methamphetamine and the Brain: New Knowledge; New Treatments Richard A. Rawson, Ph.D Adjunct.
Long-Term Consequences of Heroin and Cocaine Addiction Yih-Ing Hser, Ph.D. UCLA Integrated Substance Abuse Programs Drug Abuse in the 21st Century: What.
Magellan Training: Medicaid Rehabilitation Option MRO.
1 Jan Eldred Karen W. Linkins Lisa Mangiante December 10, 2008.
Intimate Partner Violence & Methamphetamine Claudia J. Wilcox, CADC II Policy & Program Development Specialists April 27, 2007.
Mental Health, Mental Illness and Chronic Disease Policy CMHA National Conference August 2008 Barbara Neuwelt, CMHA, Ontario.
Health Care Reform Primary Care and Behavioral Health Integration John O’Brien Senior Advisor on Health Financing SAMHSA.
Top ten myths about mental illness. Myth #1: Psychiatric disorders are not true medical illnesses Like heart disease and diabetes. People who have a mental.
Addiction: It’s a Brain Disease Beyond a Reasonable Doubt.
RAMAR  SINCE 1980, RAMAR HAS BEEN A VITAL PART OF RECOVERY FOR CHRONICALLY ADDICTED RECOVERY FOR CHRONICALLY ADDICTED INDIVIDUALS IN NEED IN SUMMIT COUNTY.
Methamphetamine: What do we do? Thomas E. Freese, Ph.D. Pacific Southwest Addiction Technology Transfer Center UCLA Integrated Substance.
Cathy Worthem, MSW Joyce Washburn, MPA BFSS, May 2011 Phoenix, AZ.
Nora D. Volkow, M.D. Director National Institute on Drug Abuse Nora D. Volkow, M.D. Director National Institute on Drug Abuse Research Advances in What.
Crack Cocaine, HIV, and African American Women Alison Hamilton, Ph.D. UCLA Department of Psychiatry Integrated Substance Abuse Programs.
Understanding Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Methamphetamine: User Characteristics and Treatment Response Alice Huber, Ph.D. Steven Shoptaw, Ph.D. Richard A. Rawson, Ph.D. Paul Brethen, M.A. Walter.
Addiction Treatment Workforce Characteristics for California, Arizona, & New Mexico: Implications for Workforce Development NAADAC/CAADAC/NALGAP National.
Special patient groups Module 5. Introduction Worldwide, the majority of people in substitute treatment are men between Even they do not form a.
UCLA Integrated Substance Abuse Programs Richard Rawson, Ph.D. Rachel Gonzales, Ph.D. Funded by: California Alcohol and Drug Programs CalOMS Training for.
DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration OFFICE OF APPLIED STUDIES Treatment Episode Data Set.
Kathryn P. Jett Director California Department of Alcohol and Drug Programs.
Understanding Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
Psychiatric Consequences of Methamphetamine Abuse Thomas E. Freese, Ph.D. Pacific Southwest Addiction Technology Transfer Center UCLA Integrated Substance.
Stimulants By Samantha M. and Drumil B UCLA 2014.
Persons with Serious Mental Illness Michael B. Blank, PhD Center for Mental Health Policy and Services Research University of Pennsylvania HIV Screening.
The Science of Addiction. Homelessness Crime Violence Homelessness Crime Violence Neurotoxicity AIDS, Cancer Mental illness Neurotoxicity AIDS, Cancer.
WOMEN’S HEALTH ISSUES : WHAT YOU REALLY NEED TO KNOW ABOUT DEPRESSION AND SUICIDE.
Module 1–1 1TIP45 Training Curriculum U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Center for.
CRISIS SERVICES FOR SUBSTANCE USE DISORDERS KEN BACHRACH, PH.D., CLINICAL DIRECTOR TARZANA TREATMENT CENTERS
Therese Fitzgerald, LCSW, MSW
US Census Data Ortman, Jennifer M., Victoria A. Velkoff, and Howard Hogan. An Aging Nation: The Older Population in the United States, Current Population.
Substance Use, Decision Making and the Testing Guidelines
Information for Network Providers
Efforts to Reduce Meth Use and Sexual Risk
Presentation transcript:

Methamphetamine Thomas E. Freese, Ph.D. Director, Pacific Southwest Addiction Technology Transfer Center Director of Training, UCLA Integrated Substance Abuse Programs 4TC Collaboration Meeting Albuquerque, NM October 17-19, 2006

How can we help each other? Training issues related to methamphetamine How can the 4TCs collaborate?

Training Issues We don’t have a problem…

Primary Amphetamine/Methamphetamine TEDS Admission Rates: 1992 (per 100,000 aged 12 and over) < 12 No data > 58 SOURCE: 2002 SAMHSA Treatment Episode Data Set (TEDS).

< < 12 No data > 58 Primary Amphetamine/Methamphetamine TEDS Admission Rates: 1997 (per 100,000 aged 12 and over) SOURCE: 2002 SAMHSA Treatment Episode Data Set (TEDS).

58-99 < or more Primary Amphetamine/Methamphetamine TEDS Admission Rates: 2002 (per 100,000 aged 12 and over) SOURCE: 2002 SAMHSA Treatment Episode Data Set (TEDS).

Treatment is a lagging indicator What do lab data show us?

Clandestine Lab Incidents: , < >1000 Source: national Clandestine Laboratory Database (

Clandestine Lab Incidents: , , , < >1000 Source: national Clandestine Laboratory Database (

Clandestine Lab Incidents: , , , < >1000 Source: national Clandestine Laboratory Database (

Clandestine Lab Incidents: ,272 2, , , , < >1000 Source: national Clandestine Laboratory Database (

Clandestine Lab Incidents: , ,335 2, , < >1000 Source: national Clandestine Laboratory Database (

Training Issues We don’t have a problem… Rumors speak louder than truth

Methamphetamine Rumors It causes holes in the brain Use it once and you are addicted Only truckers and gay men use It is not associated with sex in heterosexuals

Rumor based policy? A pervasive rumor has surfaced in many geographic areas with elevated MA problems: MA users are virtually untreatable with negligible recovery rates. Rates from 5% to less than 1% have been quoted in newspaper articles and reported in conferences. **The resulting conclusion is that spending money on treating MA users is futile and wasteful, BUT… no data exists that supports these statistics**

Training Issues We don’t have a problem… Rumors speak louder than truth Which meth problem are we talking about?

There are at least 3 meth “epidemics” Urban Rural Performance enhancement Longer hours of work Weight loss Better sex These overlap and intersect with each other

Training Issues We don’t have a problem… Rumors speak louder than truth Which meth problem are we talking about? Meth treatment is the same as treatment for other drugs…isn’t it?

Statistics During the fiscal year: 35,947 individuals were admitted to treatment in California under the Substance Abuse and Crime Prevention Act funding. Of this group, 53% reported MA as their primary drug problem

Statistics Analysis of: Drop out rates Retention in treatment rates Re-incarceration rates Other measures of outcome All these measures indicate that MA users respond in an equivalent manner as individuals admitted for other drug abuse problems.

Methamphetamine and Treatment Treatment outcomes with meth users identical to results with cocaine users. Outcomes using traditional methods are poor. Training resources seriously inadequate to educate clinicians in areas affected by meth Retention in treatment is the ballgame

Treatments for Methamphetamine Cognitive Behavioral Therapies Contingency Management Motivational Interviewing MATRIX Model

Methamphetamine and the Brain: Implications for Treatment

Dopamine Transporters in Methamphetamine Abusers p < Normal Control Methamphetamine Abuser Time Gait(seconds) Dopamine Transporter (Bmax/Kd) Motor Activity Delayed Recall (words remembered) Dopamine Transporter Bmax/Kd Memory

PET Scan of Long-Term Meth Brain Damage

Training Issues We don’t have a problem… Rumors speak louder than truth Which meth problem are we talking about? Meth treatment is both the same as treatment for other drugs…isn’t it? HIV and Meth are intimately connected across many populations.

Methamphetamine and HIV in MSM: Time-to-Response Association? * Deren et al., 1998, Molitor et al., 1998; ** Reback et al., in prep, *** Reback, 1997; **** Shoptaw et al., 2002; ****VNRH, unpublished data

Q.10: I am more likely to have sex (e.g., intercourse, oral sex, masturbation, etc.) when using …

Results from the CADDs Data System (2001) *The statewide data collection system, CADDs has information on the relative usefulness of treatment for MA users, by comparing them to cocaine users.

Predictors of Retention in Treatment for more than 90 days 1. Higher rates of retention for men 2. Legal supervision increases treatment retention 3. Those who began use at an older age were retained better than those who started when younger 4. Those who are older at admission were retained better 5. Injection users were retained more poorly 6. Those with chronic mental illness were retained more poorly 7. Daily users are retained more poorly than those who use less often than daily

Training Issues We don’t have a problem… Rumors speak louder than truth Which meth problem are we talking about? Meth treatment is both the same as treatment for other drugs…isn’t it? HIV and Meth are intimately connected across many populations. When are we going to find the sure for addiction?

Investigational Medication for High Blood Pressure Treatment Works!!!

New Behavioral Treatment for Methamphetamine Use Treatment Failed!!!

Relapse Rates Are Similar for Drug Dependence and Other Chronic Illnesses Relapse Rates Are Similar for Drug Dependence and Other Chronic Illnesses Drug Dependence Drug Dependence Type I Diabetes Type I Diabetes Hypertension Asthma 40 to 60% 30 to 50% 50 to 70% Source: McLellan, A.T. et al., JAMA, Vol 284(13), October 4, Percent of Patients Who Relapse

Opportunities for Collaboration

Special Treatment Consideration Should be Made for the Following Groups of Individuals: Female MA users (higher rates of depression; very high rates of previous and present sexual and physical abuse; responsibilities for children). Injection MA users (very high rates of psychiatric symptoms; severe withdrawal syndromes; high rates of hepatitis).

Special Treatment Consideration Should be Made for the Following Groups of Individuals: MA users who take MA daily or in very high doses. Homeless, chronically mentally ill and/or individuals with high levels of psychiatric symptoms at admission. Individuals under the age of 21. Gay men (at very high risk for HIV and hepatitis).

What works in prevention? We need to work together to figure it out.

Montana Methamphetamine Initiative Media campaign Paint the State

Montana Meth Paint the State

An Example of a Successful Collaboration Trainings on the Border on Substance abuse and HIV for last three years. Various community trainings: HIV Task Force Mental Health Nurses Primary care physicians Meth Tip Sheet PAETC and PSATTC

Thomas E. Freese, Ph.D.